Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Takayasu Arteritis With Pulmonary Artery Involvement, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).
Detailed description
The present study intends to conduct a prospective analysis of the clinical data in TAK patients in order to:
1. describe the clinical characteristics and current status of multimodal treatment in patients with TAK-PAI, thereby enhancing the understanding of TAK-PAI; 2. to investigate the risk factors for mortality in patients with TAK-PAI, so as to promote early intervention and reduce mortality. 3. explore factors associated with pulmonary hypertention (PH) in patients with TAK-PAI, so as to facilitate the early identification of patients who may develop PH.
Primary outcome measures
- All-cause death [Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.]
Secondary outcome measures (3)
- Six-minute walk distance [Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026]
- WHO functional class [Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.]
- N-terminal pro-brain natriuretic peptide level [Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026]
Eligibility criteria
Inclusion criteria
- Hospitalized between Jan 1, 2016 and Dec 31, 2026
- Diagnosed with TAK according to the modified Ishikawa criteria and/or 1990 American College of Rheumatology criteria and/or 2022 ACR/EULAR criteria
- Diagnosed with pulmonary artery involvement using computed tomography pulmonary angiography or transcatheter pulmonary angiography
- Patients without aortic or primary branch involvement who nonetheless exhibited both clinical features and computed tomography-confirmed evidence of pulmonary artery involvement (PAI), after exclusion of other diseases causing pulmonary artery stenosis or occlusion
Exclusion criteria
- Patients with PAI caused by non-TAK diseases such as other types of vasculitis, fibrosing mediastinitis, pulmonary artery sarcoma, pulmonary sarcoidosis or chronic thromboembolic pulmonary hypertension
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- China-Japan Friendship hospital — Beijing
Publications
- Zheng S, Li Y, Liu Z, Chen Y, Song Y, Zhang S, Xie W, Zhai Z. Pulmonary hypertension in Takayasu arteritis with pulmonary artery involvement: risk factors and impact on mortality. BMJ Open Respir Res. 2026 Apr 1;13(1):e003854. doi: 10.1136/bmjresp-2025-003854. PMID 41922023
Identifiers
NCT: NCT07184814 · 2022-NHLHCRF-LX-01-01-02